Biogen Inc. (BIIB) stock
BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Oct 28, 2026Score 4/3057% above fair value
$247.13−4.28 (-1.70%)
Close on Nov 19, 2026Market cap $36.53BP/E 105.6Yield –
Biogen price to book ratio
The price-to-book ratio is market cap divided by shareholders' equity.
Biogen's price to book ratio was 2.1× on Apr 30, 2024, against 3.3× a year earlier. Over the last 5 years it ranged from 2.1× to 5.1×, with a median of 3.5×.
Price to Book Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2024 | Apr 30, 2024 | 2.1× | −0.5 |
| 2023 | Dec 29, 2023 | 2.6× | −0.6 |
| 2022 | Dec 30, 2022 | 3.2× | −0.3 |
| 2021 | Dec 31, 2021 | 3.5× | −0.3 |
| 2020 | Dec 31, 2020 | 3.8× | −0.3 |
| 2019 | Dec 31, 2019 | 4.1× | −0.5 |
| 2018 | Dec 31, 2018 | 4.6× | −0.8 |
| 2017 | Dec 29, 2017 | 5.3× | +0.2 |
| 2016 | Dec 30, 2016 | 5.1× | −1.7 |
| 2015 | Dec 31, 2015 | 6.8× | −0.9 |
| 2014 | Dec 31, 2014 | 7.7× | −0.5 |
| 2013 | Dec 31, 2013 | 8.2× | +2.8 |
| 2012 | Dec 31, 2012 | 5.4× | +0.9 |
| 2011 | Dec 30, 2011 | 4.5× | +0.7 |
| 2010 | Dec 31, 2010 | 3.8× | +1.4 |
| 2009 | Dec 31, 2009 | 2.4× | – |
See a number that looks wrong?